Essential Biomarker Testing in GI Cancers

CCO Oncology Podcast

English - August 18, 2021 21:15 - 17 minutes - 15.7 MB
Courses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

Next Episode: Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:

Current testing approaches, including IHC and PD-L1 assays and next-generation sequencingTumor agnostic testing: MSI, TMB, and NTRK fusion testingColon cancer: RAS, BRAF, and HER2Gastric cancer: PD-L1, HER2, and morePancreatic cancer: BRCABiliary cancers: FGFR and IDH1Liquid biopsiesWhen to test

Presenter:

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Content based on an online CME program supported by educational grants from Bayer and Merck, Sharp & Dohme.

Link to full program:
https://bit.ly/3j4hV8J